Have a feature idea you'd love to see implemented?
Let us know!
CRDF Cardiff Oncology Inc
Price (delayed)
$2.5
Market cap
$127.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.94
Enterprise value
$116.48M
Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to
Highlights
The gross profit has increased by 50% YoY and by 3.6% QoQ
Cardiff Oncology's revenue has increased by 50% YoY and by 3.6% from the previous quarter
The quick ratio has contracted by 49% YoY and by 4.1% from the previous quarter
The equity has declined by 37% year-on-year and by 6% since the previous quarter
Key stats
What are the main financial stats of CRDF
Market
Valuations
Earnings
Shares outstanding
51.13M
Market cap
$127.83M
Enterprise value
$116.48M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.36
Price to sales (P/S)
170.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
169.06
Revenue
$689,000
EBIT
-$42.98M
EBITDA
-$42.57M
Free cash flow
-$34.65M
Per share
Balance sheet
Liquidity
EPS
-$0.94
Free cash flow per share
-$0.74
Book value per share
$1.06
Revenue per share
$0.01
TBVPS
$1.34
Total assets
$62.9M
Total liabilities
$13.5M
Debt
$1.69M
Equity
$49.39M
Working capital
$46.81M
Debt to equity
0.03
Current ratio
4.74
Quick ratio
4.65
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
-6,178.5%
Gross margin
100%
Net margin
-6,238.2%
Operating margin
-6,736%
Return on assets
-60.4%
Return on equity
-74%
Return on invested capital
-103.5%
Return on capital employed
-85.3%
Return on sales
-6,238.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRDF stock price
How has the Cardiff Oncology stock price performed over time
Intraday
-1.19%
1 week
-11.97%
1 month
-9.75%
1 year
117.39%
YTD
68.92%
QTD
-6.37%
Financial performance
How have Cardiff Oncology's revenue and profit performed over time
Revenue
$689,000
Gross profit
$689,000
Operating income
-$46.41M
Net income
-$42.98M
Gross margin
100%
Net margin
-6,238.2%
The gross profit has increased by 50% YoY and by 3.6% QoQ
Cardiff Oncology's revenue has increased by 50% YoY and by 3.6% from the previous quarter
Cardiff Oncology's net margin has increased by 30% YoY
The operating margin rose by 30% year-on-year
Growth
What is Cardiff Oncology's growth rate over time
Valuation
What is Cardiff Oncology stock price valuation
P/E
N/A
P/B
2.36
P/S
170.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
169.06
Cardiff Oncology's EPS has decreased by 3.3% QoQ and by 2.2% YoY
The equity has declined by 37% year-on-year and by 6% since the previous quarter
The stock's price to book (P/B) is 12% more than its 5-year quarterly average of 2.1 and 2.6% more than its last 4 quarters average of 2.3
The P/S is 55% less than the 5-year quarterly average of 378.4 and 21% less than the last 4 quarters average of 214.5
Cardiff Oncology's revenue has increased by 50% YoY and by 3.6% from the previous quarter
Efficiency
How efficient is Cardiff Oncology business performance
The company's return on invested capital has shrunk by 102% YoY and by 23% QoQ
Cardiff Oncology's return on equity has shrunk by 66% YoY and by 18% QoQ
CRDF's return on assets has dropped by 51% year-on-year and by 15% since the previous quarter
Cardiff Oncology's return on sales has increased by 30% YoY
Dividends
What is CRDF's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRDF.
Financial health
How did Cardiff Oncology financials performed over time
The company's current ratio fell by 49% YoY and by 4.6% QoQ
The quick ratio has contracted by 49% YoY and by 4.1% from the previous quarter
Cardiff Oncology's debt is 97% lower than its equity
The equity has declined by 37% year-on-year and by 6% since the previous quarter
Cardiff Oncology's debt has decreased by 27% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.